Table 4. Progression on MKI.
| Progression ( 22 ) | No progression ( 22 ) | p-value | ||
|---|---|---|---|---|
| Age (years) | 59 | 66 | 0.561 | |
| Sex (F) | 50% | 72.7% | 0.215 | |
| Primary tumor size (cm) | 4.5 | 3.7 | 0.057 | |
| Number of metastatic sites | 0.03 | |||
| 1 | 13.6% | 45.5% | ||
| 2 | 45.5% | 31,8% | ||
| 3 | 22.7% | 18.2% | ||
| 4 | 18.2% | 4.5% | ||
| Pulmonary metastasis only | 4.5% | 36.36% | 0.02 | |
| Max. SUV - PET + Target lesion | 14.62 | 11.0 | 0.042 | |
| PET + Target lesion | 100% | 85.7% | 0.033 | |
| Lowest Tg during MKI | 664.9 | 165.5 | 0.049 | |
| Symptomatic disease | 54.5% | 36.4% | 0.364 | |
| Number of AE | 3.0 | 4.0 | 0.213 | |
| Mean RAI activity | 365.79 | 473.81 | 0.057 | |
MKI: multikinase inhibitors; Tg: thyroglobulin; RAI: radioiodine, AE: adverse events.